NCT07639021进行中（未招募）2 期
Evaluation of Different Dose Escalation Regimens for NNC0662-0419 in Participants With Obesity
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 233
- 试验地点
- 50
研究概览
简要总结
The purpose of the study is to find out if NNC0662-0419 is safe and effective for treating participants living with obesity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female (sex assigned at birth, inclusive of all gender identities).
- •Age 18 years or above at the time of signing the informed consent.
- •Body mass index (BMI) greater than or equal to (≥) 30.0 kilogram per square meter (kg/m^2) at screening.
- •Participant must have a desire and be committed to lose at least 25 percentage (%) of their body weight from randomisation.
排除标准
- •Known or suspected hypersensitivity to study intervention(s) or related products.
- •Treatment with any medication prescribed for the indication of obesity or weight management (e.g. glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues)) within 90 days before screening.
- •Glycated haemoglobin (HbA1c) ≥ 6.5% (48 Millimoles per mole [mmol/mol]) as measured by the central laboratory at screening.
- •History of type 1 or type 2 diabetes mellitus.
研究组 & 干预措施
NNC0662-0419 placebo
Placebo Comparator
Participants will receive NNC0662-0419 placebo administered subcutaneously in a dose-escalation manner.
干预措施: NNC0662-0419 Placebo (Drug)
NNC0662-0419
Experimental
Participants will receive NNC0662-0419 administered subcutaneously in a dose-escalation manner.
干预措施: NNC0662-0419 (Drug)
Semaglutide
Experimental
Participants will receive semaglutide administered subcutaneously in a dose-escalation manner.
干预措施: Semaglutide (Drug)
Semaglutide placebo
Placebo Comparator
Participants will receive semaglutide placebo administered subcutaneously in a dose-escalation manner.
干预措施: Semaglutide placebo (Drug)
研究者
研究点 (50)
Loading locations...
相似试验
招募中
1 期
A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus ErythematosusNCT07339332Union Hospital, Tongji Medical College, Huazhong University of Science and Technology12
尚未招募
1 期
Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic CancerNCT07587827Centre Georges Francois Leclerc77
招募中
1 期
First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate CancerMetastatic Prostate CancerNCT07529717AstraZeneca42
招募中
1 期
A Study of JNJ-95804306 for Relapsed or Refractory Hematological MalignanciesNCT07572006Janssen Research & Development, LLC360
招募中
1 期
The Safety, Dosimetry and Efficacy of 177Lu-INN805 in Patients With Malignant Solid TumorsBreast CancerThyroid CancerSarcomaNCT07459283FindCure Biosciences (ZhongShan) Co., Ltd.10